SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
04 01 2021
Historique:
received: 03 08 2020
accepted: 14 10 2020
pubmed: 17 10 2020
medline: 16 1 2021
entrez: 16 10 2020
Statut: ppublish

Résumé

A considerable fraction of B cells recognize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with germline-encoded elements of their B cell receptor, resulting in the production of neutralizing and nonneutralizing antibodies. We found that antibody sequences from different discovery cohorts shared biochemical properties and could be retrieved across validation cohorts, confirming the stereotyped character of this naive response in coronavirus disease 2019 (COVID-19). While neutralizing antibody sequences were found independently of disease severity, in line with serological data, individual nonneutralizing antibody sequences were associated with fatal clinical courses, suggesting detrimental effects of these antibodies. We mined 200 immune repertoires from healthy individuals and 500 repertoires from patients with blood or solid cancers - all acquired prior to the pandemic - for SARS-CoV-2 antibody sequences. While the largely unmutated B cell rearrangements occurred in a substantial fraction of immune repertoires from young and healthy individuals, these sequences were less likely to be found in individuals over 60 years of age and in those with cancer. This reflects B cell repertoire restriction in aging and cancer, and may to a certain extent explain the different clinical courses of COVID-19 observed in these risk groups. Future studies will have to address if this stereotyped B cell response to SARS-CoV-2 emerging from unmutated antibody rearrangements will create long-lived memory.

Identifiants

pubmed: 33064671
pii: 142966
doi: 10.1172/JCI142966
pmc: PMC7773397
doi:
pii:

Substances chimiques

Antibodies, Viral 0

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Front Immunol. 2017 Oct 16;8:1286
pubmed: 29085363
Cell. 2020 Aug 20;182(4):843-854.e12
pubmed: 32673567
Front Immunol. 2019 Aug 21;10:1897
pubmed: 31497012
Bioinformatics. 2019 Feb 1;35(3):526-528
pubmed: 30016406
Cell Host Microbe. 2020 Jun 10;27(6):863-869
pubmed: 32464098
MD Comput. 1997 Jul-Aug;14(4):306-17
pubmed: 9230594
Nucleic Acids Res. 2018 Jul 2;46(W1):W264-W270
pubmed: 29668996
J Theor Biol. 1966 Feb;10(2):370-83
pubmed: 5964400
Hepatology. 2020 Jul 21;:
pubmed: 32692457
Bioinformatics. 2020 Aug 17;:
pubmed: 32805021
Eur J Immunol. 2016 Feb;46(2):480-92
pubmed: 26614343
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
BMC Bioinformatics. 2015 May 28;16:175
pubmed: 26017500
Oncoimmunology. 2019 Jul 25;8(11):e1644110
pubmed: 31646093
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Front Immunol. 2017 Jan 17;7:681
pubmed: 28144239
Immunity. 2020 Aug 18;53(2):442-455.e4
pubmed: 32668194

Auteurs

Lisa Paschold (L)

Department of Internal Medicine IV, Oncology/Hematology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Donjete Simnica (D)

Department of Internal Medicine IV, Oncology/Hematology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Edith Willscher (E)

Department of Internal Medicine IV, Oncology/Hematology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Maria Jgt Vehreschild (MJ)

Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.

Jochen Dutzmann (J)

Mid-German Heart Center, Department of Cardiology and Intensive Care Medicine, University Hospital, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Daniel G Sedding (DG)

Mid-German Heart Center, Department of Cardiology and Intensive Care Medicine, University Hospital, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Christoph Schultheiß (C)

Department of Internal Medicine IV, Oncology/Hematology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Mascha Binder (M)

Department of Internal Medicine IV, Oncology/Hematology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH